The finding that the growth of BT‐474 breast cancer cells in in vitro and in a xenograft model is highly sensitive to a combination of Akt (MK‐2206) and SGK (14h) inhibitors that induced inhibition of cell growth and tumour regression emphasises the therapeutic potential of a strategy of targeting both the Akt and SGK kinases for the treatment of cancer. This evidence concerns the gene AKT1 and breast carcinoma.